Epizyme eyes lucrative use for newly-launched Tazverik

US biotech Epizyme is gearing up for a potentially lucrative second indication for its Tazverik (tazemetostat), after the FDA agreed to a fast review in follicular lymphoma.

Jazz targets US launch of SCLC drug after FDA grants fast re...

PharmaMar and Jazz Pharmaceuticals have announced the FDA has granted a six-month Priority Review for their lurbinectedin for relapsed small cell lung cancer (SCLC).

World Orphan Drug Congress USA 2020

Short description of the specified event

Gilead closes in on second CAR-T approval in US

Roche's SMA drug risdiplam hits targets in children ahead of...

It’s not far off crunch time for Roche’s potential spinal muscular atrophy (SMA) drug, risdiplam, which the big Swiss pharma hopes will generate blockbuster revenues as well as taking marke

Durect's post-op painkiller splits FDA advisory panel

As the US opioid addiction crisis continues, it seems the FDA is less than convinced about the new painkilling drugs that the pharma industry is developing.